ABSTRACT
A retrospective study was performed to report the results obtained with intravenous immunoglobulin therapy with Guillain-Barre syndrome, and to look at the clinical profile and outcome of those patients. the clinical profile of 26 patients with proved Guillain-Barr'e syndrome were reviewed, all were admitted to the Pediatric department at King Hussein Medical Center. Amman, Jordan over the period from June 1988-June 1997. The presenting complaints, neurological examination, cerebrospinal fluid and neurophysiological studies and follow up assessment were analyzed. It has been shown that the male to female ratio is 1.6:1.0, all patients presented with flaccid symmetrical ascending paralysis with loss of deep tendon reflexes. Twelve patients [46.1%] had sensory manifestations, 10 patients [38.4%] developed cranial nerves palsy, and 6 patients [23%] had autonomic involvement, CSF measurement of protein in the first 10 days of the illness was high in 17 patients [65.3%] and normal in 9 patients [34.6%]. Nerve conduction of all patients showed demyelization polyneuropathy of varying severity, 3 patients [11.53%] developed permanent motor neurological deficit, one patients [3.8%] died. Immunoglobulin was given to 12 patients [46.1%] and it showed their efficacy at a dosage of 0.4 gm/kg/day for 5 days. Guillain-Barre syndrome has a good prognosis and mortality and morbidity rates are comparative to rates in other studies. Treatment with immunoglobulins is easy, safe and morbidity is lower